KRAS and neoplasm: In particular, a study on 135 patients with B-MPT showed that 21.4% of them were PD-L1-positive via Dako 22C3 assay (CPS ≥ 1) and that several tumors harbored genomic alterations with approved indications in other tumor types, including pathogenic PIK3CA, EGFR Exon 19/20 insertions, KRAS G12C (N = 1), FGFR fusions (N = 1), BRAF V600E mutations (N = 4), and BRCA2 (N = 1).13